EcoDrugPlus

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSPMRG00000008779
Gene Symbol: INPP5D
3 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Insulin Like Growth Factor 1 Receptor

Ensembl ID : ENSPMRG00000013211
Gene Symbol: IGF1R
3 Cross references
274 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Insulin Receptor

Ensembl ID : ENSPMRG00000021675
Gene Symbol: INSR
1 Cross references
289 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Alpha 2b

Ensembl ID : ENSPMRG00000014873
Gene Symbol: ITGA2B
1 Cross references
189 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Alpha 4

Ensembl ID : ENSPMRG00000003077
Gene Symbol: ITGA4
3 Cross references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Alpha 5

Ensembl ID : ENSPMRG00000007612
Gene Symbol: ITGA5
3 Cross references
269 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Alpha V

Ensembl ID : ENSPMRG00000000852
Gene Symbol: ITGAV
1 Cross references
243 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Beta 1

Ensembl ID : ENSPMRG00000012054
Gene Symbol: ITGB1
2 Cross references
298 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Beta 3

Ensembl ID : ENSPMRG00000011496
Gene Symbol: ITGB3
3 Cross references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Beta 5

Ensembl ID : ENSPMRG00000006175
Gene Symbol: ITGB5
3 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Beta 6

Ensembl ID : ENSPMRG00000009340
Gene Symbol: ITGB6
3 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Beta 7

Ensembl ID : ENSPMRG00000001666
Gene Symbol: ITGB7
3 Cross references
160 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).